Latest news with #AcadiaHealthcare
Business Wire
2 days ago
- Business
- Business Wire
Acadia Healthcare Investor Alert: Scott+Scott Attorneys at Law LLP Investigates Acadia Healthcare Company, Inc.'s Directors and Officers for Breach of Fiduciary Duties
NEW YORK--(BUSINESS WIRE)-- Scott+Scott Attorneys at Law LLP ('Scott+Scott'), an international securities and consumer rights litigation firm, is investigating whether the leadership of Acadia Healthcare Company, Inc. ('Acadia Healthcare') (NASDAQ: ACHC) breached their fiduciary duties to Acadia Healthcare and its shareholders. Scott+Scott is investigating whether members of the Acadia Healthcare board of directors or senior management failed to manage Acadia Healthcare in an acceptable manner, in breach of their fiduciary duties to Acadia Healthcare, and whether Acadia Healthcare and its shareholders have suffered damages as a result. New York Times published an investigative article detailing unlawful and unethical practices at Acadia Healthcare, including improperly detaining psychiatric patients in Acadia Healthcare facilities against their will. A second article was published on December 7, 2024, detailing fraud and falsification of records at Acadia Healthcare methadone clinics. On April 22, 2025, the New York Times published a third article regarding Acadia Healthcare, alleging suicides and rapes at one of Acadia Healthcare's facilities outside Chicago due in part to insufficient staffing. Acadia Healthcare has acknowledged several governmental investigations on the above, including by the Criminal Division of the U.S. Department of Justice and the Securities and Exchange Commission, as well as Congressional inquiries. In addition, a securities class action lawsuit has been filed against Acadia Healthcare and its top management. What You Can Do – CLICK HERE FOR YOUR OPTIONS AS A SHAREHOLDER If you own shares of Acadia Healthcare, you may have legal claims against Acadia Healthcare's directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at (844) 818-6982 or jpettigrew@ About Us Scott+Scott is an international law firm known for its expertise in representing corporate clients, institutional investors, businesses, and individuals harmed by anticompetitive conduct or other forms of wrongdoings, including securities law and shareholder violations. With more than 100 attorneys in nine offices in the United States, as well as three offices in Europe, our advocacy has resulted in significant monetary settlements on behalf of our clients, along with other forms of relief. Our highly experienced attorneys have been recognized for being among the top financial lawyers in 2024 by Lawdragon, WWL: Commercial Litigation 2024, and Legal 500 in Antitrust Civil Litigation, and have received top Chambers 2024 rankings. In addition, we have been recognized by the American Antitrust Institute for the successful litigation of high-stakes anticompetitive claims in the United States. To learn more about Scott+Scott, our attorneys, or complex case resolution, please visit Attorney Advertising
Yahoo
29-05-2025
- Business
- Yahoo
Substance Abuse Treatment Market Forecast 2025-2030 with Tariff-Adjusted Growth Projections for the Short and Long Term
Features Profiles of Key Players Universal Health Services, Acadia Healthcare Company, American Addiction Centers, Advanced Recovery Systems, Hazelden Betty Ford Foundation and More Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Substance Abuse Treatment Market by Treatment Mode, Substance Type, Service Provider, End User, Payment Mode - Global Forecast to 2030" report has been added to Substance Abuse Treatment Market grew from USD 7.72 billion in 2024 to USD 8.52 billion in 2025. It is expected to continue growing at a CAGR of 10.09%, reaching USD 13.75 billion by substance abuse treatment arena is undergoing a fundamental transformation driven by the integration of digital health solutions and a shift toward holistic, patient-centered care. Telehealth platforms that once served as novelty offerings have rapidly become integral channels for therapy, counseling, and ongoing support, breaking down geographic barriers and democratizing access to specialized harm reduction strategies are gaining traction, fostering a care continuum that emphasizes stabilization and long-term recovery rather than acute intervention alone. This shift has prompted providers to develop hybrid models that blend intensive detoxification services with outpatient programs, ensuring continuity of care as patients transition across treatment the policy front, the gradual relaxation of prescribing restrictions for certain medications and the expansion of reimbursement pathways have incentivized the adoption of integrated treatment frameworks. Payors and policymakers are recognizing the cost-effectiveness of early intervention, spurring collaborations between public agencies and private stakeholders to scale preventive and post-acute support these developments underscore a strategic pivot from siloed interventions to interconnected ecosystems of care. Stakeholders equipped to harness these trends will lead the next wave of innovation, delivering more resilient, scalable, and personalized treatment the Ripple Effects of 2025 US Tariff ChangesThe implementation of new United States tariffs in 2025 has introduced a complex set of cost pressures across the substance abuse treatment supply chain. Equipment used in medical detoxification units, ranging from specialized monitoring devices to pharmaceutical imports, has experienced incremental price adjustments that ripple through operational budgets. Facilities reliant on imported components for advanced telehealth infrastructure have also felt the impact, resulting in strategic renegotiations with technology fiscal dynamics extend beyond hardware to the procurement of therapeutic supports, including digital cognitive behavioral therapy modules and virtual reality applications. As service providers absorb higher input costs, there is a discernible shift toward optimizing existing resources and exploring domestically produced alternatives. This realignment has stimulated partnerships with local manufacturers and software developers eager to offer compliant, cost-effective collaboration has similarly adapted, with cross-border research initiatives now factoring in tariff-induced variances when budgeting for multi-site clinical trials. Funding agencies and institutional stakeholders are recalibrating grant allocations to accommodate these emerging cost vectors without undermining the integrity of scientific the tariff framework introduces short-term constraints, it also catalyzes innovation in supply chain resilience and domestic capacity building. Organizations that proactively diversify sourcing strategies and engage in strategic alliances will be best positioned to mitigate financial headwinds and sustain high-quality treatment Regional Dynamics Shaping Treatment UptakeRegional landscapes display marked variation in treatment uptake, shaped by regulatory environments, funding priorities, and cultural perceptions. In the Americas, well-established reimbursement frameworks support a robust network of inpatient, outpatient, and telehealth services, with public-private collaborations driving continuous refinement of care standards. North America's advanced clinical infrastructure coexists with growing demand in Latin American urban centers, where nascent outpatient and homecare models are gaining Europe, Middle East, and Africa, policy heterogeneity yields pockets of excellence alongside underserved regions. Western Europe combines stringent quality controls with widespread insurance coverage, enabling diverse service providers to flourish. In contrast, parts of the Middle East and Africa are at earlier stages of infrastructure development, prompting international aid agencies and local stakeholders to co-invest in capacity building and Asia-Pacific region presents a mosaic of innovation and challenge. Developed markets leverage telehealth to bridge gaps in rural areas, while emerging economies confront stigma and limited funding. Governments are increasingly recognizing substance abuse as a public health priority, allocating resources to expand medical detoxification and outpatient programming. In metropolitan centers, digital platforms are accelerating patient engagement, and mobile health initiatives are redefining outreach regional insights emphasize the necessity of localized approaches that respect regulatory idiosyncrasies and cultural mores, enabling providers to tailor interventions for maximum on Leading Innovators Steering the Market ForwardA cohort of forward-looking organizations is setting new benchmarks in treatment delivery. Prominent hospital based centers are integrating advanced telemonitoring solutions to enhance continuity of care post-detoxification, while standalone rehabilitation facilities are forming strategic alliances with telehealth startups to extend behavioral counseling services. Specialty homecare providers are leveraging digital outreach programs that combine real-time data analytics with human coaching, resulting in improved adherence and relapse national chains have adopted cross-disciplinary care pathways, embedding psychiatric and social work expertise within inpatient and outpatient settings. This holistic approach underscores a broader industry trend toward converging medical and psychosocial interventions under unified operational frameworks. Concurrently, digital therapeutics companies are piloting app-based cognitive behavioral therapy protocols, with early results indicating measurable improvements in treatment extends to payer-provider collaborations, where value-based contracting models are incentivizing outcomes rather than service volume. These arrangements are compelling service providers to invest in outcome tracking and predictive analytics, thereby refining care strategies and optimizing resource allocation. Partnerships between rehabilitation centers and academic institutions are also fostering evidence-driven program enhancements, ensuring that clinical practices evolve in lockstep with research these company-level initiatives reflect an ecosystem in which technology, clinical excellence, and strategic alliances converge to elevate standards of care and patient Imperatives for Industry TrailblazersIndustry leaders must embrace a multipronged strategy that aligns clinical innovation with sustainable business models. First, expanding telehealth capabilities beyond basic video consultations to encompass remote monitoring, digital therapeutics, and virtual peer support communities will strengthen patient engagement and reduce attrition. Integrating these services with traditional care pathways can create seamless transitions across levels of program design is equally essential. Providers should leverage segmentation intelligence to develop targeted interventions for high-risk demographic groups and substance categories, ensuring that therapy modalities and counseling frameworks resonate with patient needs. Embedding family and community support mechanisms can further enhance recovery outcomes, particularly in outpatient and aftercare the operational front, diversifying procurement strategies and forging partnerships with domestic technology vendors can mitigate tariff-driven cost pressures. Aligning with payors to craft value-based reimbursement models will incentivize quality over volume, fostering long-term fiscal health and accountability. Collaboration with policymakers and advocacy groups can also accelerate regulatory reforms that expand access and destigmatize investing in robust data analytics infrastructure will empower decision-makers to track outcomes, identify emerging trends, and iterate on program design in near real-time. This data-driven approach will underpin continuous improvement, ensuring organizations remain adaptive in a rapidly evolving Segmentation & CoverageThis research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations: Treatment Mode Day Treatment Detoxification Medical Detox Non Medical Detox Inpatient Hospital Based Inpatient Residential Inpatient Outpatient Intensive Outpatient Program Standard Outpatient Program Telehealth Asynchronous Telehealth Synchronous Telehealth Substance Type Alcohol Cannabis Opioids Stimulants Service Provider Clinic Homecare Hospital Based Centre Standalone Rehab Center End User Adolescents Adults Geriatric Payment Mode Private Insurance Public Funding Self Pay This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions: Americas United States California Texas New York Florida Illinois Pennsylvania Ohio Canada Mexico Brazil Argentina Europe, Middle East & Africa United Kingdom Germany France Russia Italy Spain United Arab Emirates Saudi Arabia South Africa Denmark Netherlands Qatar Finland Sweden Nigeria Egypt Turkey Israel Norway Poland Switzerland Asia-Pacific China India Japan Australia South Korea Indonesia Thailand Philippines Malaysia Singapore Vietnam Taiwan This research report delves into recent significant developments and analyzes trends for each of the following companies: Universal Health Services, Inc. Acadia Healthcare Company, Inc. American Addiction Centers, Inc. Advanced Recovery Systems, LLC Hazelden Betty Ford Foundation CleanSlate Centers, LLC Recovery Centers of America, LLC Phoenix House Foundation Caron Treatment Centers, Inc. Odyssey House, Inc. Key Attributes Report Attribute Details No. of Pages 181 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $8.52 Billion Forecasted Market Value (USD) by 2030 $13.75 Billion Compound Annual Growth Rate 10% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
Is the Options Market Predicting a Spike in Acadia Healthcare Stock?
Investors in Acadia Healthcare Company, Inc. ACHC need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 20, 2025 $65 Call had some of the highest implied volatility of all equity options today. Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. Clearly, options traders are pricing in a big move for Acadia Healthcare shares, but what is the fundamental picture for the company? Currently, Acadia Healthcare is a Zacks Rank #3 (Hold) in the Medical - Hospital industry that ranks in the Top 35% of our Zacks Industry Rank. Over the last 30 days, no analysts have increased their earnings estimates for the current quarter, while two analysts have revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from 77 cents per share to 71 cents in that the way analysts feel about Acadia Healthcare right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your to see the trades now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Neogen, Dentsply Sirona, Acadia Healthcare, Universal Health Services, and Mettler-Toledo Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains. However, President Trump clarified that tariffs could go "substantially higher" if a full deal with China wasn't reached during the 90-day pause, but not all the way back to the previous levels. Still, the agreement has cooled fears of a prolonged trade war, helping stabilize expectations for global growth and trade flows and fueling renewed optimism. The optimism appeared concentrated in key trade-sensitive sectors, particularly technology, retail, and industrials, as lower tariffs reduce cost pressures and restore cross-border demand. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Medical Devices & Supplies - Diversified company Neogen (NASDAQ:NEOG) jumped 9.1%. Is now the time to buy Neogen? Access our full analysis report here, it's free. Dental Equipment & Technology company Dentsply Sirona (NASDAQ:XRAY) jumped 6%. Is now the time to buy Dentsply Sirona? Access our full analysis report here, it's free. Hospital Chains company Acadia Healthcare (NASDAQ:ACHC) jumped 8.2%. Is now the time to buy Acadia Healthcare? Access our full analysis report here, it's free. Hospital Chains company Universal Health Services (NYSE:UHS) jumped 5.9%. Is now the time to buy Universal Health Services? Access our full analysis report here, it's free. Research Tools & Consumables company Mettler-Toledo (NYSE:MTD) jumped 8.6%. Is now the time to buy Mettler-Toledo? Access our full analysis report here, it's free. Neogen's shares are very volatile and have had 27 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Neogen is down 45.6% since the beginning of the year, and at $6.50 per share, it is trading 63.3% below its 52-week high of $17.71 from July 2024. Investors who bought $1,000 worth of Neogen's shares 5 years ago would now be looking at an investment worth $202.81. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
12-05-2025
- Business
- Yahoo
Acadia Healthcare (NASDAQ:ACHC) Posts Q1 Sales In Line With Estimates
Behavioral health company Acadia Healthcare (NASDAQ:ACHC) met Wall Street's revenue expectations in Q1 CY2025, but sales were flat year on year at $770.5 million. The company's outlook for the full year was close to analysts' estimates with revenue guided to $3.35 billion at the midpoint. Its non-GAAP profit of $0.40 per share was 12% above analysts' consensus estimates. Is now the time to buy Acadia Healthcare? Find out in our full research report. Revenue: $770.5 million vs analyst estimates of $769.7 million (flat year on year, in line) Adjusted EPS: $0.40 vs analyst estimates of $0.36 (12% beat) Adjusted EBITDA: $134.2 million vs analyst estimates of $132.1 million (17.4% margin, 1.6% beat) The company reconfirmed its revenue guidance for the full year of $3.35 billion at the midpoint Adjusted EPS guidance for the full year is $2.65 at the midpoint, roughly in line with what analysts were expecting EBITDA guidance for the full year is $700 million at the midpoint, in line with analyst expectations Free Cash Flow was -$163.2 million compared to -$463.7 million in the same quarter last year Sales Volumes fell 1.1% year on year, in line with the same quarter last year Market Capitalization: $2.20 billion With a network of over 250 facilities serving patients in 38 states and Puerto Rico, Acadia Healthcare (NASDAQ:ACHC) operates facilities providing mental health and substance use disorder treatment services across the United States. A company's long-term sales performance can indicate its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Regrettably, Acadia Healthcare's sales grew at a tepid 2% compounded annual growth rate over the last five years. This fell short of our benchmarks and is a rough starting point for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Acadia Healthcare's annualized revenue growth of 8.2% over the last two years is above its five-year trend, suggesting some bright spots. We can better understand the company's revenue dynamics by analyzing its number of admissions, which reached 48,507 in the latest quarter. Over the last two years, Acadia Healthcare's admissions averaged 2.2% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases. This quarter, Acadia Healthcare's $770.5 million of revenue was flat year on year and in line with Wall Street's estimates. Looking ahead, sell-side analysts expect revenue to grow 8.2% over the next 12 months, similar to its two-year rate. This projection is admirable and implies the market sees success for its products and services. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Acadia Healthcare has done a decent job managing its cost base over the last five years. The company has produced an average operating margin of 13%, higher than the broader healthcare sector. Analyzing the trend in its profitability, Acadia Healthcare's operating margin decreased by 5.7 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 3.6 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Acadia Healthcare's EPS grew at a decent 6.8% compounded annual growth rate over the last five years, higher than its 2% annualized revenue growth. However, we take this with a grain of salt because its operating margin didn't expand and it didn't repurchase its shares, meaning the delta came from reduced interest expenses or taxes. In Q1, Acadia Healthcare reported EPS at $0.40, down from $0.84 in the same quarter last year. Despite falling year on year, this print easily cleared analysts' estimates. Over the next 12 months, Wall Street expects Acadia Healthcare's full-year EPS of $2.86 to shrink by 4.7%. It was encouraging to see Acadia Healthcare beat analysts' EPS and EBITDA expectations this quarter. Zooming out, we think this was a decent quarter. The stock traded up 4.8% to $27.11 immediately after reporting. So do we think Acadia Healthcare is an attractive buy at the current price? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
